Shingles vaccine safety in pregnancy under review for immunocompromised women

NCT ID NCT05811754

Ongoing Knowledge-focused Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether the shingles vaccine (HZ/su) is safe for pregnant women aged 18-49 with weakened immune systems. Researchers will track about 2,800 women to see if the vaccine raises the risk of birth defects or other problems in their babies. The goal is to provide real-world safety data for this group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HZ/su vaccine (Shingrix)
What this could lead to: If successful, this study could provide reassurance that the HZ/su vaccine is safe to use during pregnancy in immunocompromised women.
What could go wrong: This is an observational study, not a controlled trial, so it can only show associations, not cause and effect. Results may be limited by the number of pregnancies studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm HIV infectious disease inflammatory bowel disease multiple sclerosis psoriasis psoriatic arthritis rheumatoid arthritis systemic lupus erythematosus herpes zoster prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HERPES ZOSTER

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Canton, Massachusetts, 02021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.